Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Perfusion Imaging | 13 | 2023 | 50 | 2.550 |
Why?
|
| Echocardiography | 7 | 2023 | 455 | 1.880 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 12 | 2024 | 191 | 1.880 |
Why?
|
| Heart Valve Diseases | 5 | 2021 | 86 | 1.790 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2024 | 34 | 1.750 |
Why?
|
| Coronary Artery Disease | 6 | 2015 | 265 | 1.580 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 74 | 1.190 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2021 | 40 | 1.060 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 77 | 1.040 |
Why?
|
| Heart | 4 | 2023 | 274 | 0.990 |
Why?
|
| Aortic Valve Stenosis | 4 | 2021 | 167 | 0.830 |
Why?
|
| Image Enhancement | 2 | 2014 | 190 | 0.790 |
Why?
|
| Echocardiography, Doppler | 3 | 2019 | 130 | 0.770 |
Why?
|
| Aorta | 1 | 2021 | 103 | 0.740 |
Why?
|
| Exercise Test | 5 | 2016 | 232 | 0.740 |
Why?
|
| Aortic Valve | 3 | 2021 | 163 | 0.680 |
Why?
|
| Radiopharmaceuticals | 3 | 2024 | 172 | 0.580 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2014 | 3 | 0.580 |
Why?
|
| Hyperaldosteronism | 1 | 2016 | 5 | 0.540 |
Why?
|
| Mesalamine | 1 | 2015 | 4 | 0.510 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2024 | 42 | 0.500 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2024 | 80 | 0.500 |
Why?
|
| Sympathetic Nervous System | 2 | 2014 | 33 | 0.490 |
Why?
|
| Humans | 40 | 2024 | 59008 | 0.490 |
Why?
|
| Chest Pain | 1 | 2015 | 85 | 0.480 |
Why?
|
| Myocarditis | 1 | 2015 | 61 | 0.470 |
Why?
|
| Consensus | 3 | 2024 | 190 | 0.470 |
Why?
|
| Radiation Protection | 1 | 2014 | 23 | 0.460 |
Why?
|
| Exercise | 2 | 2012 | 908 | 0.460 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 151 | 0.460 |
Why?
|
| Artifacts | 1 | 2015 | 126 | 0.460 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 100 | 0.450 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 3 | 2024 | 10 | 0.450 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 202 | 0.450 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2015 | 112 | 0.440 |
Why?
|
| Purines | 1 | 2012 | 38 | 0.420 |
Why?
|
| Pyrazoles | 1 | 2012 | 73 | 0.400 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 170 | 0.390 |
Why?
|
| Heart Ventricles | 3 | 2023 | 247 | 0.370 |
Why?
|
| Stroke Volume | 3 | 2019 | 317 | 0.360 |
Why?
|
| Athletes | 1 | 2012 | 95 | 0.360 |
Why?
|
| Exercise Therapy | 1 | 2011 | 98 | 0.350 |
Why?
|
| Cardiovascular Infections | 3 | 2024 | 3 | 0.350 |
Why?
|
| Endocarditis | 3 | 2024 | 19 | 0.340 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1022 | 0.340 |
Why?
|
| Mitral Valve | 2 | 2024 | 101 | 0.330 |
Why?
|
| Neurons | 1 | 2014 | 854 | 0.310 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 855 | 0.290 |
Why?
|
| Hospitalization | 1 | 2014 | 1273 | 0.280 |
Why?
|
| Ventricular Function, Left | 2 | 2019 | 262 | 0.280 |
Why?
|
| Leukocytes | 2 | 2024 | 107 | 0.280 |
Why?
|
| Heart Failure | 1 | 2014 | 860 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2022 | 0.270 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 1540 | 0.260 |
Why?
|
| Male | 19 | 2021 | 27369 | 0.260 |
Why?
|
| Prognosis | 5 | 2024 | 1563 | 0.260 |
Why?
|
| Female | 18 | 2021 | 30662 | 0.240 |
Why?
|
| Vasodilator Agents | 2 | 2016 | 61 | 0.230 |
Why?
|
| Angina, Stable | 2 | 2014 | 10 | 0.230 |
Why?
|
| Delphi Technique | 1 | 2024 | 81 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2015 | 1896 | 0.220 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.220 |
Why?
|
| Middle Aged | 12 | 2021 | 16184 | 0.220 |
Why?
|
| Hypertension | 2 | 2021 | 598 | 0.210 |
Why?
|
| Heart Atria | 1 | 2023 | 137 | 0.210 |
Why?
|
| Registries | 2 | 2017 | 802 | 0.200 |
Why?
|
| Ventricular Remodeling | 2 | 2021 | 80 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 389 | 0.190 |
Why?
|
| Dilatation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 84 | 0.180 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2021 | 122 | 0.180 |
Why?
|
| Bioprosthesis | 1 | 2021 | 39 | 0.180 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 86 | 0.170 |
Why?
|
| Cardiac Catheterization | 2 | 2019 | 239 | 0.170 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2019 | 32 | 0.160 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 93 | 0.160 |
Why?
|
| Atrial Pressure | 1 | 2019 | 4 | 0.160 |
Why?
|
| Risk Factors | 6 | 2021 | 4983 | 0.160 |
Why?
|
| Retrospective Studies | 6 | 2021 | 5949 | 0.160 |
Why?
|
| Ventricular Pressure | 1 | 2019 | 30 | 0.160 |
Why?
|
| Heart Valves | 1 | 2018 | 22 | 0.160 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 5058 | 0.160 |
Why?
|
| Hemodynamics | 2 | 2016 | 216 | 0.150 |
Why?
|
| Adult | 7 | 2021 | 15659 | 0.140 |
Why?
|
| Acetanilides | 2 | 2014 | 3 | 0.140 |
Why?
|
| Data Accuracy | 1 | 2017 | 27 | 0.140 |
Why?
|
| Inservice Training | 1 | 2017 | 81 | 0.140 |
Why?
|
| Piperazines | 2 | 2014 | 95 | 0.140 |
Why?
|
| Coronary Circulation | 1 | 2016 | 49 | 0.140 |
Why?
|
| Aldosterone | 1 | 2016 | 15 | 0.140 |
Why?
|
| Mathematics | 1 | 2016 | 28 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2316 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 1091 | 0.130 |
Why?
|
| Viridans Streptococci | 1 | 2015 | 5 | 0.130 |
Why?
|
| Medical Laboratory Personnel | 1 | 2015 | 8 | 0.130 |
Why?
|
| Vascular Fistula | 1 | 2015 | 7 | 0.130 |
Why?
|
| Shock | 1 | 2015 | 31 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 894 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 81 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 256 | 0.130 |
Why?
|
| Endocarditis, Bacterial | 1 | 2015 | 29 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2021 | 5129 | 0.120 |
Why?
|
| Streptococcal Infections | 1 | 2015 | 76 | 0.120 |
Why?
|
| Aortic Diseases | 1 | 2015 | 67 | 0.120 |
Why?
|
| Calcinosis | 1 | 2015 | 78 | 0.120 |
Why?
|
| Dyspnea | 1 | 2015 | 108 | 0.120 |
Why?
|
| Nausea | 1 | 2015 | 108 | 0.120 |
Why?
|
| Triage | 1 | 2015 | 110 | 0.120 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2015 | 49 | 0.120 |
Why?
|
| Aged | 9 | 2019 | 13259 | 0.120 |
Why?
|
| Vomiting | 1 | 2015 | 133 | 0.120 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 116 | 0.120 |
Why?
|
| ROC Curve | 3 | 2023 | 259 | 0.110 |
Why?
|
| Standard of Care | 1 | 2014 | 26 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2014 | 98 | 0.110 |
Why?
|
| Drug Costs | 1 | 2014 | 58 | 0.110 |
Why?
|
| Electric Countershock | 1 | 2014 | 98 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2014 | 121 | 0.110 |
Why?
|
| Multimodal Imaging | 2 | 2024 | 67 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 171 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2015 | 204 | 0.110 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2012 | 6 | 0.110 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 169 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 674 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2017 | 412 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2013 | 249 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2012 | 168 | 0.100 |
Why?
|
| Physical Endurance | 1 | 2012 | 48 | 0.100 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 68 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 119 | 0.100 |
Why?
|
| Myocardium | 1 | 2013 | 261 | 0.100 |
Why?
|
| Sex Factors | 2 | 2012 | 957 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 256 | 0.090 |
Why?
|
| Morbidity | 1 | 2011 | 105 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2014 | 837 | 0.090 |
Why?
|
| Length of Stay | 1 | 2014 | 761 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2010 | 256 | 0.090 |
Why?
|
| United States | 4 | 2024 | 7458 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 532 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2012 | 354 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 701 | 0.070 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 745 | 0.070 |
Why?
|
| Quality of Life | 1 | 2014 | 1103 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 823 | 0.070 |
Why?
|
| Disease Progression | 1 | 2011 | 1037 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1518 | 0.070 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2015 | 91 | 0.060 |
Why?
|
| Prevalence | 2 | 2021 | 1278 | 0.060 |
Why?
|
| Ranolazine | 2 | 2014 | 2 | 0.060 |
Why?
|
| Prosthesis-Related Infections | 1 | 2024 | 31 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1453 | 0.050 |
Why?
|
| Time Factors | 3 | 2015 | 3552 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2014 | 683 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 337 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 210 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 326 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2013 | 576 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2014 | 731 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 201 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 635 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 89 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 983 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 2429 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 19 | 0.030 |
Why?
|
| Debridement | 1 | 2015 | 25 | 0.030 |
Why?
|
| Connecticut | 1 | 2015 | 86 | 0.030 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2015 | 17 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 50 | 0.030 |
Why?
|
| New York | 1 | 2015 | 136 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 201 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2015 | 74 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 168 | 0.030 |
Why?
|
| Machine Learning | 1 | 2015 | 135 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 72 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 200 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 161 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 56 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 521 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2015 | 147 | 0.030 |
Why?
|
| Perfusion | 1 | 2013 | 77 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 443 | 0.030 |
Why?
|
| Technetium | 1 | 2012 | 68 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 787 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2012 | 74 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2012 | 13 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 99 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 370 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 286 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 142 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 485 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 806 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2013 | 160 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2013 | 199 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2015 | 485 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2015 | 669 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 435 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 712 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 561 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4294 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2567 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3078 | 0.020 |
Why?
|